文献速递核素与放射性配体治疗放射性药物与辐射防护

二甲双胍与接受[177Lu]Lu-PSMA治疗患者的肾脏剂量学:降低肾脏吸收剂量而不影响肿瘤剂量学

Metformin and renal dosimetry in patients undergoing [177Lu]Lu-PSMA therapy: reduced kidney absorbed dose without impact on tumor dosimetry.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-06-26

该回顾性研究分析57例接受PSMA放射性配体治疗的患者(15例使用二甲双胍,42例未使用),通过治疗后剂量学评估肾脏和肿瘤吸收剂量。结果显示二甲双胍组肾脏平均吸收剂量显著更低(中位0.290 vs. 0.367 Gy/GBq,p=0.046),而肿瘤平均吸收剂量无显著差异(0.739 vs. 0.997 Gy/GBq,p=0.215)。二甲双胍可能是降低肾脏辐射暴露、改善PSMA靶向治疗指数的有前景策略。

要点

  • 二甲双胍组肾脏平均吸收剂量显著低于对照组(中位0.290 vs. 0.367 Gy/GBq,p=0.046)。
  • 两组肿瘤平均吸收剂量无显著差异(0.739 vs. 0.997 Gy/GBq,p=0.215)。
  • 多因素线性回归显示二甲双胍使用与肾脏平均吸收剂量降低独立相关。

核心结论

  • 二甲双胍使用与PSMA放射性配体治疗患者肾脏平均吸收剂量降低相关,且不影响肿瘤吸收剂量。
  • 二甲双胍可能是降低肾脏辐射暴露、改善PSMA靶向治疗指数的有前景且广泛可用的策略。

研究设计与样本

  • 回顾性分析57例接受PSMA放射性配体治疗的患者,其中15例使用二甲双胍,42例未使用。
  • 通过治疗后剂量学评估肾脏平均吸收剂量和肿瘤平均吸收剂量(每例患者随机选择最多三个骨转移灶)。

主要发现

  • 二甲双胍组肾脏平均吸收剂量中位0.290 Gy/GBq,显著低于未使用组的0.367 Gy/GBq(p=0.046)。
  • 两组肿瘤平均吸收剂量分别为0.739 Gy/GBq和0.997 Gy/GBq,差异无统计学意义(p=0.215)。
  • 多因素线性回归分析中,二甲双胍使用与肾脏平均吸收剂量降低独立相关,而总肿瘤体积不是显著预测因子。
  • 未发现肿瘤负荷与肾脏平均吸收剂量之间的关联,提示该效应独立于肿瘤汇效应。

临床怎么用

  • 对于接受PSMA放射性配体治疗的患者,二甲双胍可能作为肾脏辐射防护的潜在策略。
  • 需前瞻性研究验证这些发现并确定最佳治疗方案。

局限性

  • 本研究为回顾性分析,样本量有限(共57例,二甲双胍组仅15例)。
  • 需要前瞻性研究验证结果并明确最佳治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy (RPT) is an established treatment for advanced prostate cancer, but renal radiation exposure remains a major safety concern, as no clinically established nephroprotective strategy exists. Preclinical data suggest metformin to reduce renal radiopharmaceutical retention by interfering with tubular reabsorption. This study aimed to investigate the effect of metformin on renal and tumor dosimetry in PSMA RPT patients. METHODS: 57 patients undergoing PSMA RPT were retrospectively analyzed (n=15 with metformin; n=42 without metformin). The mean kidney absorbed dose (AD) and mean tumor AD (up to three randomly selected osseous metastases per patient) were assessed by post-RPT dosimetry. Total tumor volume (TTV) was evaluated as a potential confounder. RESULTS: Patients on metformin showed a significantly lower mean kidney AD compared to patients without metformin (median 0.290 vs. 0.367 Gy/GBq; p=0.046). In multiple linear regression analysis, metformin use was independently associated with reduced mean kidney AD, whereas TTV was not a significant predictor. No significant difference in mean tumor AD was observed between groups (0.739 vs. 0.997 Gy/GBq; p=0.215), indicating preserved tumor targeting. No association between tumor burden and mean kidney AD was detected, suggesting independence from tumor sink effect. CONCLUSION: Metformin use was associated with a reduced mean kidney AD in patients undergoing PSMA RPT without affecting tumor ADs. Thus, metformin may represent a promising and widely available strategy to reduce renal radiation exposure and improve the therapeutic index of PSMA-targeted RPT. Prospective studies are warranted to validate these findings and define optimal treatment regimens.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Siegmund SC, Delker A, Widjaja L, et al. Metformin and renal dosimetry in patients undergoing [177Lu]Lu-PSMA therapy: reduced kidney absorbed dose without impact on tumor dosimetry. Eur J Nucl Med Mol Imaging. 2026. PMID: 42350617. doi:10.1007/s00259-026-08030-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。